Consistent with this view, multiple clinical trials with second-generation ADCs targeting FOLR1 in ovarian cancer patients are currently ongoing (Sutro Biopharma, Inc., San Francisco, CA, USA) [89]. Here, FOLR1 is linked to ovarian cancer.